Gun-sight technique for recanalization of chronic noncirrhotic, nonmalignant extrahepatic portal vein obstruction Authors: Túlio Fabiano de O. Leite, Thiago F. Nunes, Belarmino Gonçalves, Raphael B. Levigard Published: 2026 ABSTRACT Portal hypertension resulting from thrombosis of the noncirrhotic extrahepatic portal vein is a rare cause with high morbidity and mortality related to complications of portal hypertension. Portal vein recanalization is a technique aimed at restoring hepatic blood flow, however, its viability may be limited by the complexity of the occlusion. This case report describes a portal vein recanalization using the gun-sight technique, which involves placing loops in the intrahepatic and extrahepatic portal veins to serve as targets for percutaneous needle advancement after failure of portal vein recanalization via conventional access. Percutaneous portal vein recanalization with transsplenic and transhepatic access, combined with guided targeting, is a technically feasible method with short-term patency and clinical improvement for the treatment of chronic portal vein thrombosis. Introduction Portal mesenteric thrombosis is the presence of blood clots in the portal vein, splenic veins, superior mesenteric vein, or intrahepatic branches of the portal vein, which can occur in both cirrhotic and noncirrhotic patients. It is a rare event, affecting 1% of noncirrhotic patients, while in cirrhotic patients it occurs with a frequency of up to 26% [1]. The etiopathogenesis of chronic noncirrhotic extrahepatic portal vein obstruction can result from hereditary or acquired thrombophilias, pancreatitis, cholangitis, abdominal surgery, and a history of umbilical vein catheterization [2]. These patients with chronic portal thrombosis develop portal cavernoma and venous collateral circulation due to portal hypertension. This cavernous transformation of the portal vein is irreversible even with anticoagulation. The main complications are ascites, gastroesophageal varices, superior mesenteric vein thrombosis, ectopic varices, hypersplenism with thrombocytopenia, portal biliopathy, and hepatic atrophy resulting from reduced blood supply to the splanchnic system [3,4]. Chronic noncirrhotic portal vein thrombosis can be treated with medication and endoscopic elastic band ligation of gastroesophageal varices, but requires multiple sessions. With recent advances in interventional radiology, portal vein recanalization (PVR), TIPS, and percutaneous variceal embolization are effective options to prevent the progression and complications of portal hypertension. Portal vein recanalization can be challenging in patients with unfavorable anatomy or portal trunk occlusion. Alternative techniques such as simultaneous percutaneous portal and splenic access and ultrasound are used to manage complex portal vein catheterization [5]. The aim of this article is to describe portal vein angioplasty using the gun-sight technique, which involves placing loops in the intrahepatic and extrahepatic portal veins to serve as targets for percutaneous needle advancement after failure of portal vein recanalization via conventional access. Case report A 16-year-old boy, 70 kg, 1.75 m tall, with no history of gastrointestinal bleeding, blood transfusions, or endoscopic treatment such as esophageal variceal ligation. Affected by severe portal hypertension resulting from a history of umbilical vein catheterization due to after birth. Besides splenomegaly and thrombocytopenia (17,000/µL), endoscopy revealed the presence of thin varicose cords in the middle third of the esophagus, extending to the cardia where they become medium-sized with visible friability. Over the past few years, worsening of gastroesophageal varices and thrombocytopenia was noted. Screening for thrombophilia was negative. Abdominal ultrasound with Doppler flowmetry and 2D shear wave elastography showed a median of 6.1 kPa from 10 samples, suggesting liver elastography compatible with low stiffness (compatible with METAVIR F0/F1). Doppler ultrasound revealed the patency of tiny native intrahepatic portal branches in the right hepatic lobe. The classification of portal thrombosis corresponds to type 2, that is, thrombosis of the origin of the portal vein with extension to segmental branches. Type 1 includes occlusion limited to the origin of the main portal vein and/or the right or left portal branches; type 2 includes type 1 plus extension to the origin of the segmental branches. Furthermore, the patient did not present with portal biliopathy. The patient did not meet the clinical-radiological criteria for portal biliopathy. The splenic and superior mesenteric veins were patent and dilated, 16 mm and 12 mm respectively, and the caliber of the segmental branch of the right portal branch was 7 mm. The procedures were performed under general anesthesia using simultaneous transhepatic and transsplenic approaches with an NPAS access system (Cook). Access to a previously patent intrahepatic portal branch and splenic were guided by ultrasound with a 21G Chiba needle. After transhepatic and transsplenic access, 7Fr 11 cm introducers were positioned and 5000 IU of unfractionated heparin were administered. Transhepatic venography demonstrated segmentation of the intrahepatic portal vein. Transsplenic venography showed cavernous transformation of the extrahepatic portal vein and occlusion of the portal trunk (Fig. 1). Due to the proximity of the transhepatic catheter tip to the transsplenic catheter tip at the hepatic hilum in relation to intraoperative phlebographies, chronicity of portal thrombosis, fibrosis at the hilum, and cavernous transformation, nonanatomical revascularization was performed using the “gun sight” technique, employing 2 loop catheters of 20 mm and fluoroscopy-guided puncture. The puncture, using the “gun sight” technique between the 2 loops, was performed close to the hepatic hilum in order to avoid puncturing an extrahepatic portal vein and increasing the risk of bleeding into the abdomen.Fig. 1Obstruction of the extrahepatic portal vein resulting from perinatal thrombosis. (A) Posteroanterior view of transsplenic subtraction portography shows cavernous transformation of the portal vein and (B) Posteroanterior fluoroscopy image of transhepatic portography shows a patent intrahepatic portal system and truncal occlusion of the portal vein.Fig 1 – dummy alt text Obstruction of the extrahepatic portal vein resulting from perinatal thrombosis. (A) Posteroanterior view of transsplenic subtraction portography shows cavernous transformation of the portal vein and (B) Posteroanterior fluoroscopy image of transhepatic portography shows a patent intrahepatic portal system and truncal occlusion of the portal vein. Portal vein reconstruction was performed sequentially by predilation with a 4×20mm balloon angioplasty and implantation of a 12×60mm EverFlex stent (Medtronic), with the stent ends in the extrahepatic portal trunk and the intrahepatic right portal branch without perioperative complications (Fig. 2) Uncoated metallic stents were chosen to respect the branching of the intrahepatic portal vein from the hepatic hilum, where the stent was positioned. The hepatic and splenic tracts were embolized under fluoroscopy with a 4 × 6mm Amplatzer II plug (Abbott) and a 1:2 mixture of N-butyl cyanoacylate (NBCA) and Lipiodol (Guerbet, France). After embolization of the hepatic and splenic tracts, Doppler ultrasound was performed to assess for complications such as the presence of hematomas, bleeding, or pseudoaneurysms. A fluoroscopy time of 110 minutes, a total procedure time of 210 minutes, and fluoroscopy resulted in a high median total dose area product of 121 Gy/cm² and a volume of 90 mL of nonionic iodinated contrast agent (iodixanol).Fig. 2(A) Fluoroscopy image in right anterior oblique projection shows the “targeting” technique with 2 loop catheters respectively positioned through the transhepatic and transsplenic accesses and coaxially directed with a 22G Chiba needle under fluoroscopic guidance. Yellow arrow: capture loop in an intrahepatic segment of the right portal branch via transhepatic access; red arrow: capture loop in a portal vein via transsplenic access; and black arrow: 21G Chiba needle transfixing the transsplenic and transhepatic loops using the “gun sight” technique and (B) Posteroanterior view of subtraction portography after implantation of a 12 × 60 mm EverFlex uncoated stent (Medtronic) to create a portoportal bypass. Portography with improved opacification of the hepatic parenchyma.Fig 2 dummy alt text (A) Fluoroscopy image in right anterior oblique projection shows the “targeting” technique with 2 loop catheters respectively positioned through the transhepatic and transsplenic accesses and coaxially directed with a 22G Chiba needle under fluoroscopic guidance. Yellow arrow: capture loop in an intrahepatic segment of the right portal branch via transhepatic access; red arrow: capture loop in a portal vein via transsplenic access; and black arrow: 21G Chiba needle transfixing the transsplenic and transhepatic loops using the “gun sight” technique and (B) Posteroanterior view of subtraction portography after implantation of a 12 × 60 mm EverFlex uncoated stent (Medtronic) to create a portoportal bypass. Portography with improved opacification of the hepatic parenchyma. The child was discharged asymptomatic 5 days after the procedure with a prescription for Rivaroxaban 20 mg/day (factor Xa inhibitor) on a perpetual basis. The patient remains asymptomatic after portal vein recanalization. Hepatic and splenic volumetry were calculated using Horus 4.0.0 software before and 6 months after angioplasty, as well as blood samples analysis to check for any improvement in platelet count. Portal flow by Doppler ultrasound and abdominal computed tomography angiography remains present and without flow alterations, increased platelet count (17.000-31.000/µL), and 38.6% reduced splenic volume (2465.72-1514.35cm3) and 22.1% increase in liver volume (947.30-1216.52 cm3) was observed during the 6-month follow-up. (Figs. 3) Endoscopy after 6 months revealed a reduction in the caliber of the varices, with the presence of thin varicose cords in the middle third of the esophagus and cardia without visible friability, corroborating the improvement in portal hypertension after recanalization of the portal vein.Fig. 3(A and B) Intravenous contrast-enhanced computed tomography (CT) scans (portal phase) 6 months after portal recanalization showing an increase in liver volume. (C and D) Intravenous contrast-enhanced CT scans (portal phase) demonstrating a reduction in splenic volume.Fig 3 dummy alt text (A and B) Intravenous contrast-enhanced computed tomography (CT) scans (portal phase) 6 months after portal recanalization showing an increase in liver volume. (C and D) Intravenous contrast-enhanced CT scans (portal phase) demonstrating a reduction in splenic volume. Discussion In the acute phase of portal thrombosis, anticoagulation aims to limit clot progression and promote venous recanalization by the endogenous fibrinolytic system, mitigating complications that trigger portal hypertension. The rate of partial and complete recanalization is 93% and 45%, respectively, in noncirrhotic patients when anticoagulated early [6]. On the other hand, when there is no portal venous recanalization, symptoms of pulmonary hypertension (PH) may appear as ascites, gastrointestinal bleeding, splenomegaly with thrombocytopenia, and encephalopathy. Consequently, there may be atrophy of liver volume and function due to chronic ischemia from reduced hepatic perfusion [7]. The goal of portal vein recanalization (PVR) is to treat complications related to portal hypertension by addressing the portal vein obstruction itself. Although conservative therapy and the use of beta-blockers are effective, many patients may still experience complications related to portal hypertension. The literature is still scarce regarding which noncirrhotic patients should be considered for PVR in chronic portal thrombosis [6]. The improvement in interventional radiology techniques and the refinement of endovascular materials have made portal vein recanalization in complex cases feasible, even with cavernous transformation of the portal vein, which was considered a contraindication for intervention in the past. Portal vein recanalization can be challenging in patients with unfavorable anatomy or portal vein thrombosis. Alternative techniques have been reported to manage difficult portal vein revascularization, including percutaneous portal and splenic access and ultrasound, with success rates between 35% and 100% and a primary stent patency rate of 63% [3]. Another alternative is the use of the Gun-sight Technique, which involves placing loops in the intra- and extra-hepatic portal veins via transhepatic and transsplenic access, respectively, to serve as targets for the percutaneous advancement of a needle [8]. This targeted approach was first described for transcaval portosystemic shunt (DIPS), involving fluoroscopic percutaneous transhepatic puncture through loops in the portal vein and inferior vena cava, looping a guidewire to establish transhepatic access, and stent placement [9,10]. The gun-sight technique was definitive in the portal vein recanalization strategy in this case because thrombosis at the portal vein in the hepatic hilum was unfavorable in the transposition attempt in both approaches. There are some retrospective studies of portal recanalization in noncirrhotic patients without TIPS that demonstrated an 11 to 39.8% increase in liver volume, a 17% reduction in splenic volume, and a mean increase in platelet count of 22%, as well as an improvement in the signs and symptoms of portal hypertension in patients who underwent successful portal vein recanalization [3,11]. In this case report, there was an increased platelet count (17,000-31,00/µL), a 38.6% reduction in splenic volume (2465.72-1514.35 cm3), and a 22.1% increase in liver volume (947.30-1216.52 cm3) over 6 months, which is similar to statistics in the literature. This change in hepatic and splenic volume and platelet count are adequate parameters that confirm stent patency and the reduction of portal hypertension. Portal revascularization offers the advantage compared to TIPS of restoring normal blood flow to the liver, avoiding the complications inherent to portosystemic shunts such as hepatic hypoperfusion, increased cardiac preload, hepatic encephalopathy, and hepatopulmonary syndrome [7]. In such complex procedures in this type of patient, complications can be considerable, at a rate of 48%. Although the targeting technique is difficult, possible complications include intercostal bleeding, pseudoaneurysm of the hepatic artery, perisplenic or hepatic hematoma, enteroportal fistula, and hepatic infarction. The indication and duration of use of anticoagulants and antiplatelet agents is still controversial after portal vein recanalization. The use of direct-acting oral anticoagulants to treat portal vein thrombosis is a safe and effective option [9]. On the other hand, long-term anticoagulant therapy in cases of thrombophilia and recurrent thrombosis is well established [10]. In this case report, perennial anticoagulation with Rivaroxaban 20 mg/day was chosen to maintain greater stent patency and mitigate possible complications of portosystemic thrombosis. Interventional radiologists must be proficient in innovative techniques that can be useful in the recanalization of noncirrhotic extrahepatic portal veins in order to resolve the complications of portal hypertension. Standardizing a portal recanalization guideline in noncirrhotic patients would be important because there has been a reduction in spleen volume and improvement in thrombocytopenia after successful PVR. Conclusion Portal vein recanalization with stent implantation using the gun-aim technique may be an alternative for treating complications of portal hypertension resulting from chronic noncirrhotic portal vein thrombosis. However, multiple access points may still be necessary in challenging cases of chronic portal thrombosis. Authors' contributions Conception and design: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Analysis and interpretation: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Data collection: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Writing the article: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Critical revision of the article: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Final approval of the article: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Statistical analysis: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Overall responsibility: Túlio Fabiano de Oliveira Leite, Thiago Franchi Nunes, Belarmino Gonçalves, Raphael Braz Levigard. Data availability The datasets used in this manuscript are readily available from the corresponding author upon request. Supporting data are available for future validation. Patient consent A written informed consent was obtained from the patient for the publication of this case report.